Click here to close now.

SYS-CON MEDIA Authors: Carmen Gonzalez, Liz McMillan, Pat Romanski, AppDynamics Blog, Roger Strukhoff

News Feed Item

Egalet Reports Second Quarter 2014 Financial Results and Provides Business Update

--Webcast and conference call today at 8:30 a.m. EDT--

WAYNE, Pa., Aug 12, 2014 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today reported business highlights and financial results for the three months ended June 30, 2014. 

Egalet Logo.

Recent highlights include:

  • Appointed Jeffrey M. Dayno, M.D. as chief medical officer;
  • Initiated Category 2/3 abuse-deterrent study of Egalet-001;
  • Received positive results from the Category 1 abuse deterrence study which tested Egalet-001's ability to resist a broad range of common methods of chemical and physical manipulation, including showed Egalet-001 has strong abuse-deterrent characteristics to one of the most common routes of morphine abuse, intravenous injection; and
  • Announced top-line results from two of three bioequivalence studies for Egalet-001.

"Our mission is to bring medications to those living with chronic pain and offer patients and physicians peace of mind by delivering them in an abuse-deterrent formulation," said Bob Radie, Egalet's president and chief executive officer.  "Our top-line results from our Category 1 abuse deterrence studies demonstrated how our lead product candidate, Egalet-001, has strong abuse-deterrent characteristics, including resistance to one of the most common routes of morphine abuse, intravenous injection."

2014 Financial Results

  • Cash Position: Cash as of June 30, 2014 was $69.3 million compared to $77.5 million at March 31, 2014. Our primary use of capital was, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, manufacturing development and other regulatory expenses and general overhead costs. We expect our cash expenditures to increase in the near term as we fund our clinical development of Egalet-001 and Egalet-002, and continue to build-out our commercial manufacturing capability.
  • Revenue: Revenues increased from zero for the three months ended June 30, 2013 to $490,000 for the three months ended June 30, 2014, as a result of the amortization of deferred revenue and the performance of certain research and development services under our collaborative agreement with Shionogi Limited.
  • R&D Expenses: Research and development expenses increased to $7.4 million for the three months ended June 30, 2014 from $1.2 million for the three months ended June 30, 2013. The increase of $6.2 million was driven primarily by an increase in our development costs for Egalet-001 and Egalet-002 and employee and stock-based compensation expenses. 
  • G&A Expenses: General and administrative expenses increased to $4.7 million for the three months ended June 30, 2014 from $1.1 million for the three months ended June 30, 2013.  The increase was primarily attributable to the continued investment in our U.S. infrastructure, including the hiring of personnel, as well as the adoption of a stock compensation plan.
  • Interest Expense: Interest increased to $4,000 in interest income for the three months ended June 30, 2014 from an expense of $1.4 million for the three months ended June 30, 2013. This change was primarily attributable to the conversion of our related party convertible debt upon consummation of our initial public offering in February 2014, which was outstanding during the prior year period. 
  • Net (Loss) Income: Net loss increased to $11.7 million for the three months ended June 30, 2014 from a net loss of $3.7 million for the three months ended June 30, 2013. 

Upcoming Milestones

2014

  • Q3: Complete Egalet-001 15 mg bioequivalence study
  • Q4: Complete category 2/3 abuse-deterrent studies for Egalet-001
  • Q4: Initiate category 2 and 3 abuse deterrence studies for Egalet-002

2015

  • Q1: Initiate pivotal Phase 3 trials for Egalet-002

Conference Call Information
Egalet's management will host a conference call to discuss the second quarter 2014 financial results:

Date:

Tuesday, August 12, 2014

Time:

8:30 a.m. EDT

Webcast (live and archive):

http://egalet.investorroom.com/eventsandwebcasts

Dial-in numbers:

1-877-870-4263 (domestic)
1-412-317-0790 (international)

Replay dial-in numbers:

1-877-344-7529 (domestic)

1-412-317-0088 (international)

Conference Number: 10050459

 

About Egalet

Egalet's mission is to help ensure access to effective medications for individuals living with chronic pain while protecting physicians, families and communities from the burden of abuse. Prescription opioid abuse has reached epidemic levels in the United States, with 6.8 million current prescription drug abusers and drug abuse is now the leading cause of accidental death in the United States. With the majority of opioids abused in the United States originating from a prescription and most often coming from a friend or family, a safeguard against the unexpected is needed.  Egalet is committed to bringing peace of mind to the patients and physicians it serves by offering abuse-deterrent pain medications.  Using the proprietary Guardian™ Technology the Company has a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation.  The Guardian Technology is customized to resist specific routes of abuse that often occur with the underlying active pharmaceutical ingredient.  The Company's lead program, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, is in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.  It was designed to resist common methods of abuse, including one of the most common routes for morphine via injection. With no abuse-deterrent formulations of morphine currently available, Egalet-001 which is in pivotal studies, if approved, could fill a significant unmet need in the marketplace. Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, is in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet-002 was designed to resist common methods of abuse, including crushing and snorting the most common route of abuse for oxycodone. Egalet entered into a collaboration with Shionogi in November of 2013, to develop abuse-deterrent hydrocodone based products. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Egalet has a strong IP position of 58 granted patents and is continually enhancing its proprietary position.  Visit www.egalet.com for more information.

Safe Harbor

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and unknown uncertainties and risks.  Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of our clinical trials; our ability to obtain regulatory approval of our product candidates; competitive factors; general market conditions; and other risks factors described in Egalet's filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Investor and Media Contact:
BiotechComm
E. Blair Clark-Schoeb
Tel: 917-432-9275
Email: [email protected]

 

Tables Follow

 

Egalet Corporation and Subsidiaries

 

Consolidated Statements of Operations (Unaudited)






Three Months Ended


Six Months Ended




June 30,


June 30,




2013


2014


2013


2014


Related party revenues


$


$

490,000


$


$

746,000












Operating Expenses:










General and administrative


1,116,000


4,728,000


1,971,000


7,996,000


Research and development


1,200,000


7,361,000


2,163,000


10,141,000


Total operating expenses


2,316,000


12,089,000


4,134,000


18,137,000


Loss from operations


(2,316,000)


(11,599,000)


(4,134,000)


(17,391,000)












Other income (expense):










Interest expense (income)


1,367,000


(4,000)


1,367,000


7,088,000


Loss (gain) on foreign currency exchange


11,000


40,000


(11,000)


43,000




1,378,000


36,000


1,356,000


7,131,000


Loss before provision for income taxes


(3,694,000)


(11,635,000)


(5,490,000)


(24,522,000)


Provision for income taxes



16,000



51,000


Net loss


$

(3,694,000)


$

(11,651,000)


$

(5,490,000)


$

(24,573,000)












Per share information:










Net loss per share of common stock, basic and diluted


$

(2.86)


$

(0.73)


$

(4.25)


$

(1.92)


Weighted average shares outstanding, basic and diluted



1,292,307



15,887,503



1,292,307



12,780,145


 

Egalet Corporation and Subsidiaries

 

Consolidated Balance Sheets



December 31, 2013


June 30, 2014

Assets



(unaudited)

Current assets:




Cash and cash equivalents

$            15,700,000


$              69,259,000

Related party receivable


345,000

Prepaid expenses

1,774,000


526,000

Other receivables

231,000


230,000

Total current assets

17,705,000


70,360,000

Property and equipment, net

2,378,000


2,476,000

Intangible asset

209,000


208,000

Deposits and other assets

71,000


2,087,000

Total assets

$            20,363,000


$              75,131,000

Liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity








Current liabilities:




Related party senior convertible debt, net of discount

$            17,209,000


$                            —

Accounts payable

1,046,000


2,507,000

Accrued expenses

1,755,000


1,551,000

Deferred revenue


551,000

Other current liabilities

55,000


74,000

Total current liabilities

20,065,000


4,683,000

Deferred income tax liability

22,000


22,000

Deferred revenue – non-current portion

10,149,000


9,188,000

Total liabilities

30,236,000


13,893,000





Commitments and contingencies (Note 6)




Redeemable convertible preferred stock:




Redeemable convertible Series A-1 preferred stock—$0.01 par value; 1,406,894 shares and 0 shares issued and outstanding at December 31, 2013 and June 30, 2014, respectively

1,443,000


Redeemable convertible Series A-2 preferred stock—$0.01 par value; 593,106 shares and 0 shares issued and outstanding at December 31, 2013 and June 30, 2014, respectively

770,000


Redeemable convertible Series B preferred stock—$0.01 par value; 2,327,301 shares and 0 shares issued and outstanding at December 31, 2013 and June 30, 2014, respectively

12,628,000


Redeemable convertible Series B-1 preferred stock—$0.01 par value; 113,916 shares and 0 shares issued and outstanding at December 31, 2013 and June 30, 2014, respectively

116,000


Total redeemable convertible preferred stock

14,957,000


Stockholders' (deficit) equity:




Common stock—$0.01 par value and $0.001 par value at December 31, 2013 and June 30, 2014, respectively;  75,000,000 shares authorized at June 30, 2014, 1,292,307 and 17,258,663 shares issued and outstanding at December 31, 2013 and June 30, 2014, respectively

13,000


17,000

Additional paid‑in capital

7,431,000


118,017,000

Accumulated other comprehensive income

1,125,000


1,176,000

Accumulated deficit

(33,399,000)


(57,972,000)

Total stockholders' (deficit) equity

(24,830,000)


61,238,000

Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity

$            20,363,000


$              75,131,000

 

Logo- http://photos.prnewswire.com/prnh/20140219/NY67493LOGO

 

SOURCE Egalet Corporation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Many of the well-known examples of DevOps success we read in blogs on the Internet paint an idyllic picture of DevOps productivity. A team was facing a stodgy, slow-moving operations department, teams weren’t delivering software on time. Those teams moved to DevOps, became proactive about infrastructure and deployment automation, and an overnight transition to productivity ensues. People are promoted, projects are successful, and developers and system administrators dance hand-in-hand in a final...
Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 16th Cloud Expo at the Javits Center in New York June 9-11 will find fresh new content in a new track called PaaS | Containers & Microservices Containers are not being considered for the first time by the cloud community, but a current era of re-consideration has pushed them to the top of the cloud agenda. With the launch ...
The world's leading Cloud event, Cloud Expo has launched Microservices Journal on the SYS-CON.com portal, featuring over 19,000 original articles, news stories, features, and blog entries. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. Microservices Journal offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. Follow new article posts on T...
SYS-CON Events announced today that Litmus Automation will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Litmus Automation’s vision is to provide a solution for companies that are in a rush to embrace the disruptive Internet of Things technology and leverage it for real business challenges. Litmus Automation simplifies the complexity of connected devices applications with Loop, a secure and scalable clou...
In 2015, 4.9 billion connected "things" will be in use. By 2020, Gartner forecasts this amount to be 25 billion, a 410 percent increase in just five years. How will businesses handle this rapid growth of data? Hadoop will continue to improve its technology to meet business demands, by enabling businesses to access/analyze data in real time, when and where they need it. Cloudera's Chief Technologist, Eli Collins, will discuss how Big Data is keeping up with today's data demands and how in t...
SYS-CON Media announced today that @ThingsExpo Blog launched with 7,788 original stories. @ThingsExpo Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @ThingsExpo Blog can be bookmarked. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago.
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, will provide some practical insights on what, how and why when implementing "software-defined" in the dat...
SYS-CON Events announced today that robomq.io will exhibit at SYS-CON's @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. robomq.io is an interoperable and composable platform that connects any device to any application. It helps systems integrators and the solution providers build new and innovative products and service for industries requiring monitoring or intelligence from devices and sensors.
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY., and the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides private all-in-one social intranets allowing workers to securely collaborate from anywhere in the world and from any device. Social, mobile, and eas...
Wearable technology was dominant at this year’s International Consumer Electronics Show (CES) , and MWC was no exception to this trend. New versions of favorites, such as the Samsung Gear (three new products were released: the Gear 2, the Gear 2 Neo and the Gear Fit), shared the limelight with new wearables like Pebble Time Steel (the new premium version of the company’s previously released smartwatch) and the LG Watch Urbane. The most dramatic difference at MWC was an emphasis on presenting we...
While not quite mainstream yet, WebRTC is starting to gain ground with Carriers, Enterprises and Independent Software Vendors (ISV’s) alike. WebRTC makes it easy for developers to add audio and video communications into their applications by using Web browsers as their platform. But like any market, every customer engagement has unique requirements, as well as constraints. And of course, one size does not fit all. In her session at WebRTC Summit, Dr. Natasha Tamaskar, Vice President, Head of C...
So I guess we’ve officially entered a new era of lean and mean. I say this with the announcement of Ubuntu Snappy Core, “designed for lightweight cloud container hosts running Docker and for smart devices,” according to Canonical. “Snappy Ubuntu Core is the smallest Ubuntu available, designed for security and efficiency in devices or on the cloud.” This first version of Snappy Ubuntu Core features secure app containment and Docker 1.6 (1.5 in main release), is available on public clouds, ...
How do you securely enable access to your applications in AWS without exposing any attack surfaces? The answer is usually very complicated because application environments morph over time in response to growing requirements from your employee base, your partners and your customers. In his session at 16th Cloud Expo, Haseeb Budhani, CEO and Co-founder of Soha, will share five common approaches that DevOps teams follow to secure access to applications deployed in AWS, Azure, etc., and the frict...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists will discuss how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations m...
SYS-CON Events announced today the IoT Bootcamp – Jumpstart Your IoT Strategy, being held June 9–10, 2015, in conjunction with 16th Cloud Expo and Internet of @ThingsExpo at the Javits Center in New York City. This is your chance to jumpstart your IoT strategy. Combined with real-world scenarios and use cases, the IoT Bootcamp is not just based on presentations but includes hands-on demos and walkthroughs. We will introduce you to a variety of Do-It-Yourself IoT platforms including Arduino, Ras...